Kim-HienThiDaoDOPhD

Hematology • Salem, OR

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Assistant Professor, Knight Cancer Institute, Oregon Health and Science University School of Medicine

Join to view full profile

Dr. Dao is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Dao's full profile

Already have an account?

Office
875 Oak St
Ste 4030
Salem, OR 97301
Phone+1 503-561-6444

Fax+1 503-561-6440
Is this information wrong?

Education & Training

University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Scripps Mercy HospitalResidency, Internal Medicine, 2003 - 2006
Michigan State University College of Osteopathic MedicineClass of 2003

Certifications & Licensure

OR State License 2009 - 2025
CA State License 2004 - 2010
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Start of enrollment: 2014 Jul 08
Completed
Phase 2
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML Start of enrollment: 2020 May 21
Recruiting
Phase 2, Phase 3

Publications & Presentations

PubMed

8 citations
Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy.
Ryan C. Stoner, Richard D. Press, Julia E. Maxson, Jeffrey W. Tyner, Kim Hien T. Dao> ;Leukemia. 2020 Jun 1
7 citations
A case study of 10 patients administered HBOC-201 in high doses over a prolonged period: outcomes during severe anemia when transfusion is not an option.
Marc Zumberg, Jed B. Gorlin, Elizabeth A. Griffiths, Garry Schwartz, Bradley S. Fletcher, Katherine Walsh, Kim Hien T. Dao, Amanda M. VanSandt, Mauricio Lynn, Aryeh Sh...> ;Transfusion. 2020 May 1
57 citations
Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia
Kim Hien T. Dao, Jason Gotlib, Michael M.N. Deininger, Stephen T. Oh, Jorge E. Cortes, Robert H. Collins, Elliot F. Winton, Dana R. Parker, Hyunjung Lee, Anna Reister ...> ;Journal of Clinical Oncology. 2020 Apr 1
51 citations
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis
Haijiao Zhang, Beth Wilmot, Daniel Bottomly, Kim Hien T. Dao, Emily A. Stevens, Christopher A. Eide, Vishesh Khanna, Angela Rofelty, Samantha L. Savage, Anna Reister S...> ;Blood. 2019 Sep 12
5 citations
Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years.
Curtis Lachowiez, Rachel J. Cook, Brandon Hayes-Lattin, Richard T. Maziarz, Uma Borate, Elie Traer, Jessica Leonard, Laura F. Newell, Kim Hien T. Dao, Gabrielle Meyers> ;Hematology/oncology and Stem Cell Therapy. 2019 Jun 1
15 citations
Two myeloid leukemia cases with rare FLT3 fusions.
Haijiao Zhang, Aleksandra Paliga, Evie Hobbs, Stephen Moore, Susan B. Olson, Nicola Long, Kim Hien T. Dao, Jeffrey W. Tyner> ;Cold Spring Harbor Molecular Case Studies. 2018 Dec 17
702 citations
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W. Tyner, Cristina E. Tognon, Daniel Bottomly, Beth Wilmot, Stephen E. Kurtz, Samantha L. Savage, Nicola Long, Anna Reister Schultz, Elie Traer, Melissa L. Abe...> ;Nature. 2018 Oct 17
10 citations
Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
Kim Hien T. Dao, Jeffrey W. Tyner, Jason Gotlib> ;Current Hematologic Malignancy Reports. 2017 Oct 6
7 citations
Polycythemia Vera Management and Challenges in the Community Health Setting
Aaron T. Gerds, Kim Hien T. Dao> ;Oncology. 2017 Apr 1
8 citations
Myelodysplastic Syndromes: Updates and Nuances
Kim Hien T. Dao> ;The Medical Clinics of North America. 2017 Mar 1
4 citations
Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women
Julia Erin Wiedmeier, Catherine Kato, Zhenzhen Zhang, Hyunjung Lee, Jennifer Dunlap, Eric Nutt, Rogan Rattray, Sarah McKay, Christopher A. Eide, Richard D. Press, Moto...> ;Experimental Hematology. 2016 Sep 1
104 citations
Age-related mutations and chronic myelomonocytic leukemia.
Clinton C. Mason, Jamshid S. Khorashad, Srinivas K. Tantravahi, Todd W. Kelley, Matthew S. Zabriskie, Dongqing Yan, Anthony D. Pomicter, Kimberly R. Reynolds, Anna M. ...> ;Leukemia. 2016 Apr 1
18 citations
A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia
Srinivas K. Tantravahi, Philippe Szankasi, Jamshid S. Khorashad, Kim Hien T. Dao, Tibor Kovacsovics, Todd W. Kelley, Michael W. Deininger> ;Leukemia & Lymphoma. 2016 Feb 8
31 citations
Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia
Vishesh Khanna, Scott T Pierce, Kim-Hien T. Dao, Cristina E. Tognon, David E Hunt, Brian Junio, Jeffrey W. Tyner, Brian J. Druker> ;Cureus. 2015 Dec 17
34 citations
What's different about atypical CML and chronic neutrophilic leukemia?
Kim Hien T. Dao, Jeffrey W. Tyner> ;Hematology. American Society of Hematology. Education Program. 2015 Dec 5
63 citations
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia
Kim Hien T. Dao, Magdolna B. Solti, Julia E. Maxson, Elliott F. Winton, Richard D. Press, Brian J. Druker, Jeffrey W. Tyner> ;Leukemia Research Reports. 2014 Jan 1
7 citations
The PI3K/Akt1 pathway enhances steady-state levels of FANCL
Kim Hien T. Dao, Michael D. Rotelli, Brieanna Brown, Jane E. Yates, Juha Rantala, Cristina E. Tognon, Jeffrey W. Tyner, Brian J. Druker, Grover C. Bagby> ;Molecular Biology of the Cell. 2013 Aug 15
153 citations
A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition
Daniel Goff, Angela Court Recart, Anil Sadarangani, Hye Jung E. Chun, Christian L. Barrett, Maryla Krajewska, Heather Leu, Janine M. Low-Marchelli, Wenxue Ma, Alice Y....> ;Cell Stem Cell. 2013 Mar 7
3 citations
Next-Generation Medicine: Combining BCR-ABL and Hedgehog-Targeted Therapies
Kim Hien T. Dao, Jeffrey W. Tyner> ;Clinical Cancer Research. 2013 Mar 15
133 citations
ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia
Qingfei Jiang, Leslie Crews, Christian L. Barrett, Hye Jung E. Chun, Angela C. Court, Jane Isquith, Maria A. Zipeto, Daniel Goff, Mark D. Minden, Anil Sadarangani, Jes...> ;Proceedings of the National Academy of Sciences of the United States of America. 2013 Jan 15
28 citations
FANCL ubiquitinates β-catenin and enhances its nuclear function
Kim Hien T. Dao, Michael D. Rotelli, Curtis L. Petersen, Stefanie Kaech, Whitney D. Nelson, Jane E. Yates, Amy E. Hanlon Newell, Susan B. Olson, Brian J. Druker, Grove...> ;Blood. 2011 Nov 18
59 citations
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib
Daniel W. Sherbenou, Oliver Hantschel, Ines Kaupe, Stephanie G. Willis, Thomas Bumm, Lalita Prabha Turaga, Thoralf Lange, Kim Hien T. Dao, Richard D. Press, Brian J. D...> ;Blood. 2010 Oct 28
15 citations
Rac1 and Cdc42 are regulators of HRasV12-transformation and angiogenic factors in human fibroblasts
Daniel M. Appledorn, Kim Hien T. Dao, Sandra O'Reilly, Veronica M. Maher, J. Justin McCormick> ;BMC Cancer. 2010 Jan 12
189 citations
Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation
Annelie Abrahamsson, Ifat Geron, Jason Gotlib, Kim-Hien Dao, Charlene F. Barroga, Isabel G. Newton, Francis J. Giles, Jeffrey Durocher, Remi S. Creusot, Mobin Karimi, ...> ;Proceedings of the National Academy of Sciences of the United States of America. 2009 Mar 10
Join now to see all

Lectures

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Other Languages

Vietnamese

Hospital Affiliations

OHSU HospitalPortland, Oregon